Fully Automated Workflow for Integrated Sample Digestion and Evotip Loading Enabling High-Throughput Clinical Proteomics [0.03%]
全自动工作流程集成样品消化和Evotip装载，实现高通量临床蛋白质组学
Anders H Kverneland,Florian Harking,Joel Mario Vej-Nielsen et al.
Anders H Kverneland et al.
Protein identification and quantification is an important tool for biomarker discovery. With the increased sensitivity and speed of modern mass spectrometers, sample preparation remains a bottleneck for studying large cohorts. To address th...
Promises and Challenges of populational Proteomics in Health and Disease [0.03%]
人群蛋白质组在健康与疾病中的机遇和挑战
Benjamin B Sun,Karsten Suhre,Bradford W Gibson
Benjamin B Sun
Advances in proteomic assay technologies have significantly increased coverage and throughput, enabling recent increases in the number of large-scale population-based proteomic studies of human plasma and serum. Improvements in multiplexed ...
Exploring the Early Molecular Pathogenesis of Osteoarthritis Using Differential Network Analysis of Human Synovial Fluid [0.03%]
运用人类滑液差异网络分析探索骨关节炎早期分子发病机制
Martin Rydén,Amanda Sjögren,Patrik Önnerfjord et al.
Martin Rydén et al.
The molecular mechanisms that drive the onset and development of osteoarthritis (OA) remain largely unknown. In this exploratory study, we used a proteomic platform (SOMAscan assay) to measure the relative abundance of more than 6000 protei...
Quantitative Proteomic Analysis Reveals Functional Alterations of the Peripheral Immune System in Colorectal Cancer [0.03%]
colorectal cancer外周免疫系统功能改变的定量蛋白质组分析
Wenyuan Zhu,Minzhe Li,Qingsong Wang et al.
Wenyuan Zhu et al.
Colorectal cancer (CRC) is characterized by high morbidity, high mortality, and limited response to immunotherapies. The peripheral immune system is an important component of tumor immunity, and enhancements of peripheral immunity help to s...
Corrigendum to "Red Blood Cells Protein Profile Is Modified in Breast Cancer Patients" [0.03%]
“红血细胞蛋白谱在乳腺癌患者中发生变化”的勘误通知
Thais Pereira-Veiga,Susana Bravo,Antonio Gómez-Tato et al.
Thais Pereira-Veiga et al.
Circulating Autoantibody Profiling Identifies LIMS1 as a Potential Target for Pathogenic Autoimmunity in pathologic Myopia [0.03%]
循环自身抗体筛选识别出LIMS1可能是病理性近视自身免疫靶点
Jiao Qi,Hao Li,Yu Du et al.
Jiao Qi et al.
High myopia is a leading cause of blindness worldwide, among which pathologic myopia, characterized by typical myopic macular degeneration, is the most detrimental. However, its pathogenesis remains largely unknown. Here, using a HuProt arr...
Pericyte-Specific Secretome Profiling in Hypoxia Using TurboID in a Multicellular in Vitro Spheroid Model [0.03%]
基于TurboID的缺氧条件下多细胞体内类器官模型中周细胞特异性分泌组谱分析
Andreas Enström,Robert Carlsson,Carolina Buizza et al.
Andreas Enström et al.
Cellular communication within the brain is imperative for maintaining homeostasis and mounting effective responses to pathological triggers like hypoxia. However, a comprehensive understanding of the precise composition and dynamic release ...
CLIPPER 2.0: Peptide-Level Annotation and Data Analysis for Positional Proteomics [0.03%]
CLIPPER 2.0：基于位置蛋白质组学的肽水平注释和数据分析
Konstantinos Kalogeropoulos,Aleksander Moldt Haack,Elizabeta Madzharova et al.
Konstantinos Kalogeropoulos et al.
Positional proteomics methodologies have transformed protease research, and have brought mass spectrometry (MS)-based degradomics studies to the forefront of protease characterization and system-wide interrogation of protease signaling. Con...
De Novo Multi-Omics Pathway Analysis Designed for Prior Data Independent Inference of Cell Signaling Pathways [0.03%]
基于从头开始的多组学路径分析设计优先数据独立推断细胞信号传导路径
Katri Vaparanta,Johannes A M Merilahti,Veera K Ojala et al.
Katri Vaparanta et al.
New tools for cell signaling pathway inference from multi-omics data that are independent of previous knowledge are needed. Here, we propose a new de novo method, the de novo multi-omics pathway analysis (DMPA), to model and combine omics d...
Marina Hermosilla-Trespaderne,Mark Xinchen Hu-Yang,Abeer Dannoura et al.
Marina Hermosilla-Trespaderne et al.
Trilaciclib, a cyclin-dependent kinase 4/6 inhibitor, was approved as a myeloprotective agent for protecting bone marrow from chemotherapy-induced damage in extensive-stage small cell lung cancer. This is achieved through the induction of a...